Solventum Corporation
SOLV
NYSE·Healthcare·Medical - Instruments & Supplies·Mkt cap $15.9B
$92.44
▲ +0.59%
P/E
11.29
Mkt Cap
$15.9B
52-Wk Range
$62.38–$94.16
52-Week Range
$62.38 - $94.16
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 28.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Comprehensive healthcare technology portfolio
- Advanced medical device innovation
- Integrated software and hardware solutions
- Diversified revenue streams
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Healthcare technology digital transformation
Value
Attractively priced below Healthcare Facilities peer average
Momentum
Strong
+17.3% over 3m
Quality
Strong
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying SOLV right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 5, 2026
Reported EPS of $2.55 vs $1.90 consensus (+34.2% surprise). Revenue of $2.2B vs $2.2B expected (+2.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+34.2%
Revenue trend · last 8Q
—
+2%
+3%
+4%
+1%
-4%
-3%
+2%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.1B
$2.1B
$2.1B
$2.2B
$2.1B
$2.0B
$2.0B
$2.2B
Margins · last 8Q
Gross
58.2%
Operating
8.2%
Profit
4.2%
Wall Street consensus
8 analysts · 63% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
63%
Hold
38%
Sell
0%
Median Price Target
—
Latest: TD Cowen · Aug 25, 2026
vs Industry
How SOLV stacks vs Medical - Instruments & Supplies
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related